Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents

There is increasing research interest in cholesterol-lowering therapy in older patients. The newer lipid-lowering agents (the proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors evolocumab and alirocumab; the PCSK9 synthesis inhibitor inclisiran, and the adenosine triphosphate–citrate l...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoll, Felicitas, Eidam, Annette, Michael, Lola, Bauer, Jürgen M., Haefeli, Walter E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Leading Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995260/
https://www.ncbi.nlm.nih.gov/pubmed/35278206
http://dx.doi.org/10.1007/s40266-022-00928-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995260/
https://www.ncbi.nlm.nih.gov/pubmed/35278206
http://dx.doi.org/10.1007/s40266-022-00928-z

Ejemplares similares